Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine composition containing insulin intensifier and miglitol

A technology of insulin sensitizer and composition, which is applied in the direction of drug combination, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc., to achieve the effect of improving utilization, lowering blood sugar level, and reducing intake

Active Publication Date: 2010-07-21
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] In conclusion, existing oral anti-diabetic drugs have many deficiencies. Combining the pathophysiological characteristics of diabetes and its complications, it is a research hotspot in the treatment of diabetes to expand the thinking and find new types of drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing insulin intensifier and miglitol
  • Medicine composition containing insulin intensifier and miglitol
  • Medicine composition containing insulin intensifier and miglitol

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] prescription

[0027] Rosiglitazone 1.5g

[0028] Miglitol 20g

[0029] Microcrystalline Cellulose 100g

[0030] 8% hydroxypropyl methylcellulose solution appropriate amount

[0031] Low-substituted hydroxypropyl cellulose 50g

[0032] Magnesium Stearate 2g

[0033] Preparation process: rosiglitazone and miglitol were passed through a 100-mesh sieve, microcrystalline cellulose and low-substituted hydroxypropyl cellulose were passed through a 80-mesh sieve, and the prescription amount of rosiglitazone, miglitol and low-substituted hydroxypropyl cellulose was weighed. Mix hydroxypropyl cellulose and microcrystalline cellulose evenly, add an appropriate amount of 8% hydroxypropyl methylcellulose solution to granulate, dry at 60°C, granulate with a 16-mesh sieve, add prescription amount of magnesium stearate to the dry granules and mix Mix evenly and press into tablets.

Embodiment 2

[0035] Pioglitazone 10g

[0036] Miglitol 20g

[0037] Microcrystalline Cellulose 100g

[0038] PEG6% solution appropriate amount

[0039] Carboxymethyl Cellulose Calcium 15g

[0040] Magnesium Stearate 2g

[0041] Preparation process: with embodiment 1.

Embodiment 3

[0043] Pioglitazone 10g

[0044] Miglitol 20g

[0045] 150g pregelatinized starch

[0046] Sodium carboxymethyl cellulose 1% solution appropriate amount

[0047] Enteric coating powder appropriate amount

[0048] Carboxymethyl Cellulose Calcium 15g

[0049] Magnesium Stearate 2g

[0050] Preparation process: According to the conventional tablet process, it is made into tablets (ball cores) of required specifications, and then coated with enteric coating powder.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an oral blood-sugar-reducing compound medicinal preparation, which consists of an insulin sensitizer, a miglitol and auxiliary materials. Compared with the prior art, the present invention is characterized in that under a circumstance of a same curative effect, a separate dosage of the insulin sensitizer or the miglitol is reduced; at the same time compared with other hypoglycemic drugs, a side effect of the present invention is reduced; the insulin sensitizer and the miglitol have a synergistic effect: the insulin sensitizer and the miglitol respectively takecurative actions towards a patient with hyperglycemia synchronously according to the different pharmacological effects and directly provide the patient or a doctor with a scientific combined medication to improve the curative effect and provide a clinic or the patient with convenience.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition for treating diabetes. Background technique [0002] The incidence of diabetes is still increasing year by year. According to the data provided by the World Health Organization (WHO), the prevalence of diabetes in developed countries has reached 5% to 10%, while in my country it is about 3%. There are 130 million diabetic patients in the world; by 2030, the number of diabetic patients in the world will double that of 2000. It is noteworthy that the prevalence of diabetes is increasing particularly rapidly in developing countries, especially those developing countries that are going from poor to rich. Diabetes is not just a disease of the rich. In areas where the economy and living standards have undergone drastic changes, there is a real danger of diabetes outbreaks. Diabetes in my country is in an explosive epidemic. Diabetic complications plague patients and the medical community: if diabet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/454A61K31/445A61K31/4439A61K47/38A61K9/20A61K9/48A61K36/899A61P3/10
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com